Poor
Not Aligned
Patient Risk:
Moderate
Summary
Low alignment: most extracted claims are not supported by the provided FDA label excerpts, especially mechanism/indication statements and elderly-specific/route-specific/commonality/supportive-care guidance. Only a subset of GI toxicity, myelosuppression, hepatotoxicity monitoring, and severe infection/myelosuppression concepts are supported.
Category Scores
Accurate Statements
Methotrexate can cause nausea and vomiting (and related GI toxicity).
Supported by GI toxicity description including vomiting and nausea (Section 5.4).
Methotrexate can cause diarrhea, which can be severe in some cases.
Diarrhea included in GI toxicities (Section 5.4) with severe outcomes such as hemorrhagic enteritis and fatal intestinal perforation.
Methotrexate can cause mouth sores.
Stomatitis included in GI toxicity description (Section 5.4), consistent with mouth sores.
Methotrexate can cause bone marrow suppression.
Section 5.3 states TREXALL suppresses hematopoiesis and can cause cytopenias including pancytopenia/leukopenia/neutropenia/thrombocytopenia.
Methotrexate can cause severe infections and fatal infections.
Section 5.11: increased risk for life-threatening or fatal bacterial/fungal/viral infections and examples.
Methotrexate can cause severe hepatotoxicity and may be irreversible.
Section 5.5: severe and potentially irreversible hepatotoxicity including fibrosis/cirrhosis/fatal liver failure.
Regular blood tests can monitor liver tests at baseline and periodically during treatment.
Section 5.5: monitor liver tests at baseline, periodically during treatment, and as clinically indicated.
Unsupported Statements
Methotrexate is a chemotherapy agent.
No provided label excerpt supports this characterization (Sections provided do not include indications/mechanism wording for 'chemotherapy agent').
Methotrexate suppresses the immune system.
Provided excerpts describe hematopoiesis/myelosuppression and serious infections but do not explicitly support the immune-system suppression phrasing.
Methotrexate reduces inflammation.
No provided label excerpt supports this therapeutic effect/mechanism statement.
Methotrexate is used to treat rheumatoid arthritis.
No provided label excerpt includes indications (Section 1 content is blank/omitted).
Methotrexate is used to treat psoriasis.
No provided label excerpt includes indications (Section 1 content is blank/omitted).
Methotrexate is used to treat certain types of cancer.
No provided label excerpt includes indications (Section 1 content is blank/omitted).
Methotrexate can cause fatigue.
No provided label excerpt lists fatigue as an adverse reaction.
Methotrexate can cause headaches, particularly when taken in high doses.
No provided label excerpt lists headache adverse reactions or dose-response/route qualifiers.
Elderly patients taking methotrexate are at a higher risk of developing infections, particularly respiratory infections.
No provided label excerpt establishes elderly-specific increased infection risk or specifically 'respiratory infections'.
Methotrexate can increase the risk of bleeding in elderly patients, particularly those taking anticoagulant medications.
No provided label excerpt establishes elderly-specific bleeding risk or anticoagulant-specific interaction.
Elderly patients taking methotrexate are at a higher risk of developing liver damage, particularly if they have pre-existing liver disease.
Section 5.5 discusses hepatotoxicity and safety unknown in hepatic disease, but the provided excerpts do not support elderly-specific increased risk or the 'particularly' framing.
Bone marrow suppression from methotrexate increases the risk of infections and bleeding in elderly patients.
Label excerpt supports myelosuppression/cytopenias and increased risk of serious/fatal infections, but does not support an elderly-specific linkage to infection and bleeding in the provided citations.
Liver damage is a common side effect of methotrexate, particularly in patients taking high doses or for extended periods.
Section 5.5 supports severe hepatotoxicity and increased risk with total cumulative dose (and timing after a cumulative dose threshold), but does not support 'common' frequency or 'particularly' high dose/extended periods as stated.
Taking methotrexate with food can help to reduce the risk of nausea and vomiting.
No provided label excerpt supports guidance about taking with food to reduce nausea/vomiting.
Anti-nausea medications can help to reduce the risk of nausea and vomiting from methotrexate.
No provided label excerpt supports use of prophylactic antiemetics to reduce nausea/vomiting.
Drinking plenty of water can help to reduce the risk of dehydration and other side effects while taking methotrexate.
No provided label excerpt supports hydration/dehydration reduction guidance.
Contradictions
Important Omissions
No label-consistent dosing/administration details were assessed from the provided extracted claims (e.g., baseline/periodic blood counts schedules beyond monitoring statements).
Importance:
Moderate
Potential boxed warning status was not assessable because the provided label excerpts did not include boxed warning content.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by provided label excerpts, including elderly-specific risk assertions and non-labeled supportive-care (food/antiemetics/hydration). While some serious risks (myelosuppression, severe GI toxicity, hepatotoxicity, serious/fatal infections) are label-supported, unsupported qualifiers could mislead counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many statements are absent from the provided label excerpts, and several add unsupported qualifiers (elderly-specific risks, 'common' frequency, food/antiemetic/hydration guidance) and include unverified indication/mechanism claims.
Suggested Improvement
Limit claims to content explicitly present in the provided label sections (e.g., cite Section 5.3 for myelosuppression/cytopenias, Section 5.4 for nausea/vomiting/diarrhea/stomatitis and severe GI toxicity, Section 5.5 for severe hepatotoxicity and liver test monitoring, Section 5.11 for serious/fatal infections). Remove or qualify unsupported statements, especially elderly-specific and supportive-care guidance and any indication/mechanism statements not contained in the supplied label text.